CAR‑T Cell Ther­a­py in Lym­phomas, Acute Lym­phoblas­tic Leukemia, and Mul­ti­ple Myeloma

CAR‑T cell ther­a­py rep­re­sents one of the most impor­tant exam­ples of adop­tive immunother­a­py suc­cess­ful­ly trans­lat­ed into mod­ern oncol­o­gy prac­tice. The treat­ment is based on the col­lec­tion of a patient’s own T lym­pho­cytes, their genet­ic mod­i­fi­ca­tion to express a chimeric anti­gen recep­tor, and sub­se­quent rein­fu­sion after lym­phode­plet­ing chemother­a­py. This approach enables T cells to rec­og­nize select­ed tumor-asso­ci­at­ed anti­gens and ini­ti­ate a cyto­tox­ic immune response inde­pen­dent­ly of con­ven­tion­al HLA-medi­at­ed anti­gen presentation.

To date, the most estab­lished clin­i­cal role of CAR‑T ther­a­py has been in B‑cell malig­nan­cies and mul­ti­ple myelo­ma. In dif­fuse large B‑cell lym­phoma, CAR‑T cells have become a stan­dard ther­a­peu­tic option for select­ed patients with relapsed or refrac­to­ry dis­ease, includ­ing those treat­ed in the sec­ond-line set­ting after ear­ly relapse or pri­ma­ry refrac­tori­ness to immunochemother­a­py. In man­tle cell lym­phoma, CAR‑T ther­a­py is used in heav­i­ly pre­treat­ed patients, par­tic­u­lar­ly after fail­ure of Bru­ton tyro­sine kinase inhibitors. In B‑cell acute lym­phoblas­tic leukemia, CAR‑T cells have enabled deep and durable remis­sions in patients with relapsed or refrac­to­ry dis­ease, includ­ing pedi­atric and young adult pop­u­la­tions. In mul­ti­ple myelo­ma, BCMA-direct­ed CAR‑T con­structs have shown high response rates in patients pre­vi­ous­ly exposed to mul­ti­ple lines of therapy.

Despite its trans­for­ma­tive effi­ca­cy, CAR‑T cell ther­a­py is asso­ci­at­ed with a dis­tinct tox­i­c­i­ty pro­file, includ­ing cytokine release syn­drome, immune effec­tor cell-asso­ci­at­ed neu­ro­tox­i­c­i­ty syn­drome, pro­longed cytope­nias, infec­tions, and hypogam­ma­glob­u­line­mia. There­fore, care­ful patient selec­tion, time­ly refer­ral, spe­cial­ized cen­ter expe­ri­ence, and mul­ti­dis­ci­pli­nary col­lab­o­ra­tion are essen­tial for safe and effec­tive treat­ment delivery.

The devel­op­ment of CAR‑T ther­a­py illus­trates how rapid­ly the bound­aries between basic sci­ence, cel­lu­lar engi­neer­ing, trans­la­tion­al research, and clin­i­cal oncol­o­gy are evolv­ing. It also high­lights the need for inte­grat­ed coöper­a­tion between clin­i­cians, mol­e­c­u­lar diag­nos­tics experts, immu­nol­o­gists, cell ther­a­py lab­o­ra­to­ries, and health­care sys­tems to make advanced cel­lu­lar ther­a­pies broad­ly acces­si­ble to patients.

CAR‑T cell ther­a­py rep­re­sents one of the most impor­tant exam­ples of adop­tive immunother­a­py suc­cess­ful­ly trans­lat­ed into mod­ern oncol­o­gy prac­tice. The treat­ment is based on the col­lec­tion of a patient’s own T lym­pho­cytes, their genet­ic mod­i­fi­ca­tion to express a chimeric anti­gen recep­tor, and sub­se­quent rein­fu­sion after lym­phode­plet­ing chemother­a­py. This approach enables T cells to rec­og­nize select­ed tumor-asso­ci­at­ed anti­gens and ini­ti­ate a cyto­tox­ic immune response inde­pen­dent­ly of con­ven­tion­al HLA-medi­at­ed anti­gen presentation.

To date, the most estab­lished clin­i­cal role of CAR‑T ther­a­py has been in B‑cell malig­nan­cies and mul­ti­ple myelo­ma. In dif­fuse large B‑cell lym­phoma, CAR‑T cells have become a stan­dard ther­a­peu­tic option for select­ed patients with relapsed or refrac­to­ry dis­ease, includ­ing those treat­ed in the sec­ond-line set­ting after ear­ly relapse or pri­ma­ry refrac­tori­ness to immunochemother­a­py. In man­tle cell lym­phoma, CAR‑T ther­a­py is used in heav­i­ly pre­treat­ed patients, par­tic­u­lar­ly after fail­ure of Bru­ton tyro­sine kinase inhibitors. In B‑cell acute lym­phoblas­tic leukemia, CAR‑T cells have enabled deep and durable remis­sions in patients with relapsed or refrac­to­ry dis­ease, includ­ing pedi­atric and young adult pop­u­la­tions. In mul­ti­ple myelo­ma, BCMA-direct­ed CAR‑T con­structs have shown high response rates in patients pre­vi­ous­ly exposed to mul­ti­ple lines of therapy.

Despite its trans­for­ma­tive effi­ca­cy, CAR‑T cell ther­a­py is asso­ci­at­ed with a dis­tinct tox­i­c­i­ty pro­file, includ­ing cytokine release syn­drome, immune effec­tor cell-asso­ci­at­ed neu­ro­tox­i­c­i­ty syn­drome, pro­longed cytope­nias, infec­tions, and hypogam­ma­glob­u­line­mia. There­fore, care­ful patient selec­tion, time­ly refer­ral, spe­cial­ized cen­ter expe­ri­ence, and mul­ti­dis­ci­pli­nary col­lab­o­ra­tion are essen­tial for safe and effec­tive treat­ment delivery.

The devel­op­ment of CAR‑T ther­a­py illus­trates how rapid­ly the bound­aries between basic sci­ence, cel­lu­lar engi­neer­ing, trans­la­tion­al research, and clin­i­cal oncol­o­gy are evolv­ing. It also high­lights the need for inte­grat­ed coöper­a­tion between clin­i­cians, mol­e­c­u­lar diag­nos­tics experts, immu­nol­o­gists, cell ther­a­py lab­o­ra­to­ries, and health­care sys­tems to make advanced cel­lu­lar ther­a­pies broad­ly acces­si­ble to patients.

CAR-T Cell Therapy in Lymphomas, Acute Lymphoblastic Leukemia, and Multiple Myeloma
CAR-T Cell Therapy in Lymphomas, Acute Lymphoblastic Leukemia, and Multiple Myeloma
CAR-T Cell Therapy in Lymphomas, Acute Lymphoblastic Leukemia, and Multiple Myeloma

Woj­ciech Szlasa

Lekarz na Odd­ziale Hema­to­log­icznym DCOPIH, asys­tent w Kat­e­drze Biologii Moleku­larnej i Komórkowej UMW we Wrocław­iu, prowadzi bada­nia nad ter­apią CAR‑T, prze­ci­w­ci­ała­mi bis­pecy­ficzny­mi i sko­jarze­niem radioter­apii z immunoter­apią w nowot­worach hema­to­log­icznych. Doświad­cze­nie w ter­apii komórkowej zdoby­wał pod­czas stażu w Würzbur­gu — jed­nym z czołowych europe­js­kich ośrod­ków CAR‑T — oraz we współpra­cy z Uni­ver­sité de Lor­raine (Nan­cy), zaj­mu­jącą się mod­e­lowaniem moleku­larnym i elek­tro­trans­fer­em genów przez błony komórek nowot­worowych. Łączy pracę ekspery­men­tal­ną z mod­e­lowaniem obliczeniowym i translacją wyników do hema­toonkologii klinicznej.

profile
Woj­ciech Szlasa, DCOPIH, POLAND

Read the Abstracts from Our Invit­ed Speakers

Can­cer Biology

Can­cer Neuroscience

Can­cer Therapy

PORT for Busi­ness — Com­pa­ny Session